Literature DB >> 14614316

Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism.

Andrea L Volk1, Angel A Rivera, Anna Kanerva, Gerd Bauerschmitz, Igor Dmitriev, Dirk M Nettelbeck, David T Curiel.   

Abstract

The incidence of malignant melanoma has been increasing. Unfortunately, advanced melanomas are rarely curable with standard therapy; therefore, new forms of treatment such as gene therapy are needed. The success of gene delivery or oncolysis depends on the nature of the vector. Adenoviral vectors are advantageous for several reasons; however, they are dependent on CAR (coxsackie and adenovirus receptor) which is deficient or heterogeneously expressed on melanoma cells in situ. Correspondingly, transduction of freshly purified melanoma cells has been shown to be minimal or variable. In order to overcome this shortcoming, it is necessary to construct tropism modified adenoviral vectors. With this goal in mind, we generated two tropism modified vectors, Ad5lucRGD which has an RGD motif incorporated into the HI loop of the fiber knob and Ad5/3luc1 which contains the tail and shaft domain of the Ad5 fiber and the knob domain of the Ad3 fiber. Herein we demonstrate that Ad5/3luc1 infects CAR-negative primary melanoma cells 1128 times better than Ad5luc1 and 34 times better than Ad5lucRGD. Furthermore we show that Ad5/3luc1 and Ad5lucRGD infect via a CAR independent route by blocking the CAR receptor. In addition, we show that the infectivity of the cells correlates with the expression of CAR and Ad3 receptors determined by FACS analysis. Therefore, Ad5/3 is very attractive as a potential therapeutic vector for malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614316     DOI: 10.4161/cbt.2.5.440

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  23 in total

1.  Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop.

Authors:  J Woraratanadharm; S Rubinchik; H Yu; F Fan; S M Morrow; J Y Dong
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

Review 2.  Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism.

Authors:  J Michael Mathis; Phoebe L Stewart; Zheng B Zhu; David T Curiel
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

3.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

4.  Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas.

Authors:  S Nair; D T Curiel; V Rajaratnam; C Thota; A Al-Hendy
Journal:  Hum Reprod       Date:  2013-07-02       Impact factor: 6.918

5.  Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

Authors:  Xavier Allaume; Nazim El-Andaloussi; Barbara Leuchs; Serena Bonifati; Amit Kulkarni; Tiina Marttila; Johanna K Kaufmann; Dirk M Nettelbeck; Jürgen Kleinschmidt; Jean Rommelaere; Antonio Marchini
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

6.  Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

Authors:  Anniina Koski; Lotta Kangasniemi; Sophie Escutenaire; Sari Pesonen; Vincenzo Cerullo; Iulia Diaconu; Petri Nokisalmi; Mari Raki; Maria Rajecki; Kilian Guse; Tuuli Ranki; Minna Oksanen; Sirkka-Liisa Holm; Elina Haavisto; Aila Karioja-Kallio; Leena Laasonen; Kaarina Partanen; Matteo Ugolini; Andreas Helminen; Eerika Karli; Päivi Hannuksela; Saila Pesonen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

Review 7.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

8.  Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.

Authors:  Belal Azab; Rupesh Dash; Swadesh K Das; Sujit K Bhutia; Xue-Ning Shen; Bridget A Quinn; Siddik Sarkar; Xiang-Yang Wang; Michael Hedvat; Igor P Dmitriev; David T Curiel; Steven Grant; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2012-05       Impact factor: 6.384

Review 9.  Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.

Authors:  Luni Emdad; Swadesh K Das; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

Review 10.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.